Clinical trials: Conditioning
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
The hypothesis for this study is that a preparative regimen that maximizes host immunosuppression without myeloablation will be well tolerated and sufficient for engraftment of donor hematopoietic cells.
- Conditions
- Metabolic Disorders, Hematologic, Immune, or Bone Marrow Disorders, Hemoglobinopathies, Non-malignant Disorders
- Trial name
- NCT00920972
- Testing
- Treatment Plan 1: Stratum 1, Treatment Plan 2: Strata 2, 3, or 4, GVHD Regimen A: UCB Recipients
- Where
- 28 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Washington University School of Medicine
Chronic Granulomatous Disease
Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients
Treatment Study to assess of safety and efficiency of conditioning with Plerixafor and G-CSF as additional agents for prevention of graft failure after transplantation in patients with chronic granulomatous disease
- Trial name
- NCT03547830
- Testing
- Plerixafor, Gcsf
- Where
- Russia
- Volunteers
- 17 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan
BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient tool to cure standard-risk acute lymphocytic leukemia (ALL) in first CR (CR1) but the choice between BU-based or TBI-based conditioning…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Total Body Irradiation, Acute Lymphocytic Leukemia
- Trial name
- NCT02670252
- Testing
- Busulfan (BU), Cyclophosphamide (CY), Total Body Irradiation (TBI)
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia
Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT
The purpose of this prospective, open-label, single-center study is to evaluate the efficacy and safety of VEN-AZA (venetoclax and azacytidine) followed by modified BUCY (busulfan and cyclophosphamide) as conditioning regimen for…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT05823714
- Testing
- VEN+AZA+Modified BUCY
- Where
- China
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Aplastic Anemia Idiopathic
A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:
Severe and very severe aplastic anemia are life threatening disorders for which allogeneic stem cell transplant is only curative treatment. However, matched sibling donor (MSD) is available in only 25-35% cases.
- Trial name
- FluCAB-Prime (NCT03955601)
- Testing
- Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Severe Aplastic Anemia
Conditioning Regimen Containing Low Dose ATG for The Treatment of Acquired SAA Receiving sUCBT
To evaluate the safety and efficacy of Single Umbilical Cord blood transplantation (sUCBT) containing low dose ATG based conditioning regimen in the treatment of acquired Severe Aplastic Anemia (SAA).
- Trial name
- NCT06039436
- Testing
- Anti-Thymocyte Globulin (Rabbit)
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Anhui Provincial Hospital
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML)
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
The purpose of this study is to learn more about the effects of (classification determinant) CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents, and young adults.
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML)
- Trial name
- NCT02061800
- Testing
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Diane George
Anxiety Disorder
Fear Conditioning Using Computer-Generated Virtual Reality
The purpose of this study is to use a computer-generated virtual reality environment to study fear conditioning. Fear conditioning is used to explore the causes and persistence of anxiety and anxiety disorders.
- Trial name
- NCT00025844
- Where
- United States
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Myelofibrosis
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
The goal of this clinical research study is to learn if using a combination of fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control myelofibrosis or myelodysplastic syndrome in patients receiving a bone…
- Trial name
- NCT00475020
- Testing
- Busulfan, Fludarabine, Thymoglobulin (ATG)
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
COVID, Corona Virus Infection
RIC as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study
This research aims to assess the use of an experimental and non-invasive procedure, Remote Ischemic Conditioning (RIC), as an adjunct therapy in attenuating severe COVID-19 disease.
- Conditions
- COVID, Corona Virus Infection, Acute Lung Injury, Ischemia Limb
- Trial name
- NCT04659460
- Testing
- Remote Ischemic Conditioning
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
B-cell Lymphoma, Burkitt Lymphoma
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Patients will receive one of two conditioning regimens (BEAM or CBV) before receiving an autologous stem cell transplant (ASCT).
- Conditions
- B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04491370
- Testing
- Polatuzumab vedotin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- New York Medical College
Physical Conditioning, Human, Cognition
Effects of Aerobic Exercise on Cognitive Function and Brain-derived Neurotrophic Factor in Young Adults
The present study will investigate the effects of aerobic exercise on cognition and growth factors including brain-derived neurotrophic factor (BDNF) in young adults aged 15-21 years.
- Trial name
- NCT02075944
- Testing
- High intensity aerobic exercise, Low intensity aerobic exercise
- Where
- Denmark
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Southern Denmark
Periacetabular Osteotomy, Opiates
Open-label Placebo for Pain Management in Adolescents and Young Adults Undergoing Bernese Periacetabular Osteotomy
In this randomized controlled trial, 64 participants undergoing PAO at UCSF will be enrolled and randomized to receive either COLP plus treatment as usual (TAU) or TAU alone.
- Trial name
- COLP PAO (NCT07373210)
- Testing
- Treatment as usual
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, San Francisco
Leukemia, Lymphoma
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002989
- Testing
- busulfan, cyclophosphamide, idarubicin
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 207 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Hematologic Malignancy
Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens
The purpose of this study is to assess transplant-related mortality (TRM) at one year after allogeneic hematopoietic stem cell transplantation (allo-HSCT) prepared by a "reduced toxicity myeloablative" conditioning regimen in…
- Trial name
- FB4-PEDIA (NCT01572181)
- Testing
- Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)
- Where
- 15 sites in France
- Volunteers
- 50 people
- Sponsor
- Nantes University Hospital
Laparoscopic Hysterectomy
Clearance Rate of Peritoneal Fluid After Full Conditioning Pneumoperitoneum
Measurement of residual peritoneal fluid after laparoscopic surgery
- Trial name
- NCT01344499
- Testing
- Carbon dioxide, full conditioning, Adept
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gasthuisberg
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML)
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies
The primary goal of this study is to evaluate an alternative myeloablative, but reduced toxicity conditioning regimen in children, to describe the safety and efficacy of intravenous (i.v.) Treosulfan administered as part of a…
- Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML), Myelodysplastic Syndromes (MDS), Juvenile Myelomonocytic Leukaemias (JMML)
- Trial name
- NCT02333058
- Testing
- Treosulfan
- Where
- 24 sites in Austria, Czechia and 4 more
- Volunteers
- 70 people
- Sponsor
- medac GmbH
Stress Disorders, Post-Traumatic
Brain Structure and Function Before and After Treatment for Post-Traumatic Stress Disorder
This study, conducted at the University of Pennsylvania and at the National Institutes of Health in Bethesda, Maryland, will examine deficits in brain structure and function in people exposed to trauma who developed…
- Trial name
- NCT00069225
- Where
- United States
- Volunteers
- 95 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder
RATIONALE: Combining antithymocyte globulin with combination chemotherapy before donor peripheral stem cell transplantation may reduce the chance of developing graft-versus-host disease following transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00054340
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center